Empiric Antifungal Therapy for the Neutropenic Patient
March 01, 2001ByThomas J. Walsh, MD|Alan S. Wayne, MD|Stephen J. Chanock, MD|Andreas H. Groll, MD
The article written by Drs. Wingard and Leather presents a thoughtful review of the current approaches to empiric antifungal therapy in neutropenic patients. Empiric antifungal therapy has evolved as a standard of care for the prevention of invasive fungal infections in neutropenic patients who remain persistently febrile despite the use of broad-spectrum antibacterial antibiotics.[1-3] Empiric antifungal therapy in this setting provides early treatment for clinically occult invasive fungal infections and systemic prophylaxis for neutropenic patients at highest risk.